Health conditions, by the evidence

Zepbound is the only FDA-approved GLP-1 for OSA with obesity (December 2024). The OSA pathway is currently the cleanest route to weight-loss GLP-1 coverage for many insurance plans.

PCOS is the most-asked off-label GLP-1 indication. Weight loss, insulin sensitivity, and androgen levels often improve, but FDA approval is not on-label.

MASLD/MASH is the next major GLP-1 expansion. Semaglutide showed Phase 3 efficacy in resolving steatohepatitis without worsening fibrosis. FDA approval expected 2026-2027.

No GLP-1 is FDA-approved for prediabetes, but trials show 60-70% reduction in T2D progression at 3 years. The case for early intervention is strong.

Menopause-driven weight gain responds to GLP-1s similarly to other adult obesity. No menopause-specific indication exists, but real-world data show comparable efficacy.